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In the past forty years, we have advanced our understanding of cardiovascular 
pathology through epidemiological and molecular studies. Atherosclerosis is one of the 
main cardiovascular diseases, which is also an underlying cause of more severe 
cardiovascular pathologies. Atherosclerosis is the chronic inflammatory response 
initiated by the damage to the endothelium caused by an imbalance of reactive oxygen 
species (ROS). This chronic inflammation causes the accumulation of plaque in arterial 
walls. Due to the widespread of cardiovascular disease, finding better treatment options is 
of importance. The interdisciplinary field of nanomedicine has been studying the 
application of various nanoparticles for future treatment options. A new class of 
nanoparticles that has promising features for medical application is carbon nanodots 
(CND). The citric acid-ethylenediamine synthesized CNDs used in this study have 
antioxidant properties making them candidates for quenching ROS and decreasing 
cardiovascular inflammation. Previous studies have shown that carbon nanodots have low 
toxicity in numerous cell lines, but CND exposure to endothelial cells has not been 
explored. The main goal of this study is to analyze in vitro and in vivo the effect of CNDs 
on endothelial dysfunction.  
 Our in vitro results showed that the uptake of carbon nanodots by EA.hy926 
endothelial cells is both time and dose-dependent. Our experiments showed cell-viability 
  
 
consistent with previous studies showing that nanodots have low cytotoxicity after 24 hr 
exposure with lower CND concentrations up to 0.3 mg/mL. However, we also found that 
higher concentrations affect metabolic activity via MTT assay after 6 hr exposure. CNDs 
significantly inhibited TNF-α-mediated expression of intracellular adhesion molecule-1 
(ICAM-1), and interleukin 8, two key molecules that are responsible for the activation 
and the firm adhesion of monocytes to activated endothelial cells for the initiation of 
atherosclerosis, while the mRNA levels increased for monocyte chemoattractant protein-
1 (MCP-1/CCL2). Similarly to the previously mentioned results, the gene expression of 
pro-inflammatory genes in cells that were treated with carbon nanodots alone showed a 
change in gene expression. Additional data showed that NQO1 activity is increased by 
nanodots after 24 hr treatment, this phase II cytoprotective enzyme is known to maintain 
homeostasis in the vasculature. Histology of samples from our 8-week animal study in 
apolipoprotein E knockout mice (Apo E -/-) suggest that plaque formation in the aorta is 
decreased in animals dosed with CNDs. Tissue samples from the liver of mice dosed with 
CNDs appear to have a decrease in hepatic lipidosis, while the kidney which is also an 
important detoxifying organ seems to have no significant change in histology.  
 In conclusion, this study explored the bioapplication of carbon nanodots in 
endothelial cell dysfunction, and our results showed that carbon nanodots could be 
promising nanoparticles that may decrease cardiovascular inflammation. Future studies 
need to explore the role of the NF-κB pathway and the Nrf2 pathway activation to 
understand the underlying mode of action by which pro-inflammatory gene expression 
changes, and NQO1 enzymatic activity increases.  
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CHAPTER I 
 
INTRODUCTION 
 
 
Cardiovascular Disease 
 
Chronic diseases are amongst the leading cause of death and disability in the 
United States, the chronic disease that tops the list is cardiovascular disease (CVD). 
According to the 2014 U.S. mortality data, heart disease had the highest death rate for 
both sexes as well as across ethnicities. Currently, heart disease remains the main cause 
of death in the United States [1, 2]. The American Heart Association predicted that by 
2030 40% of the U.S. population would suffer from a form of cardiovascular disease, but, 
by 2015 41.5% of the American population had a form of CVD [3]. Atherosclerosis, the 
buildup of plaque (e.g., fat, cholesterol, etc.) inside arteries, is a precursor to more severe 
cardiovascular diseases. It is a multi-factorial disease that can be influenced by genetic, 
behavioral health, and environmental factors that mainly affect the heart. The hardening 
of coronary arteries is the underlying cause of multiple chronic heart health issues. The 
silent progression of atherosclerosis can lead to ischemic damage that can cause 
myocardial infarction events, ensuing the placement of drug eluding stents via 
percutaneous coronary intervention. This cardiac event would be followed by a regimen 
of high-risk medications needed to prevent a future cardiac event. By the year 2035, it is 
estimated that the cost of cardiovascular diseases will surpass the $1 trillion mark, 
making it not only a health concern but also an economic burden [3, 4]. CVDs account 
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for about 31% of worldwide deaths [5], making it of worldwide health importance to 
search for potential preventative measures and treatments to limit the growing burden.   
The Role of Inflammation in the Initiation of Atherosclerosis 
The pathogenesis of the atherosclerotic vascular disease is a complex process, but 
accumulating data shows that inflammation is an important protagonist in subsequent 
atypical endothelial cell functions (i.e., endothelial dysfunction), playing a fundamental 
role in the initiation and progression of atherosclerosis. In a healthy artery, endothelial 
cells line the internal lumen of the vasculature, and they are lined by the tunica intima. 
The hardening of the arteries occurs when endothelial cells are activated, and pro-
inflammatory mediators coordinate leukocyte migration and extravasion of leukocytes 
into the tunica intima, the site of endothelial activation. The continuous migration of 
white blood cells causes the thickening of the artery cell wall, leading to various health 
complications as the diameter of the artery is narrowed, and blood flow decreases [6]. 
The mediators that signal for inflammation are cytokines and adhesion molecules. Pro-
inflammatory mediators are secreted molecules which include thrombin, tumor necrosis 
factor-alpha (TNF-α), macrophage chemoattractant protein-1 (MCP-1 also known as 
CCL2), interleukin 8 (IL-8), E-selectin, P-selectin, vascular cell adhesion molecule-1 
(VCAM-1), and intracellular adhesion molecule-1 (ICAM-1) [7-10]. Studies show that 
TNFα is an important pro-inflammatory mediator. Currently, there is not an effective 
treatment that can decrease the expression of cytokines. Inflammation-induced 
endothelial dysfunction is important in the development of atherosclerosis, and agents 
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that can suppress the inflammatory pathway in vascular endothelial cells are candidate 
agents to prevent or treat vascular endothelial dysfunction. 
Atherosclerosis is an inflammatory disease, and it is the precursor to multiple 
cardiovascular diseases. In the presence of an atherosclerotic lesion, alterations occur 
within the endothelial cells, resulting in transcriptional activation of inflammatory genes 
through the activation of the nuclear factor kappa B (NF-κB) pathway [11-13]. 
Endothelial cells are one of the few cells not part of the immune system that can excrete 
messenger molecules to attract leukocytes to the site of inflammation. Activated (or 
dysfunctional) endothelium can also express adhesion molecules, facilitating the adhesion 
of white blood cells to the site of inflammation. The inflammatory response commences 
when leukocytes have successfully attached to the damaged endothelium, and 
transmigrate into the intima region. Leukocytes, mainly monocytes, are activated into 
macrophages once they have migrated into the intima. In the intima, the macrophages can 
phagocytize oxidized lipids, such as lipoproteins. Through lipid accumulation, these 
macrophages turn into “foam cells” which accumulate through continuous inflammation 
to create fatty streaks [14]. Macrophages consequently undergo apoptosis, and signal for 
reinforcement by secreting cytokines, which recruit more leukocytes. Eventually, the 
vessel matrix will form finalize the formation of plaque. It has also been documented that 
local sheer stress can promote the expression of adhesion molecules, augmenting the 
inflammatory response and impacting atherosclerosis development [15, 16].  In a healthy 
vessel, the blood flow typically helps regulate genes that are relevant to atherogenesis.  
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Reactive Oxygen Species and Atherosclerosis 
One of the main sources of cellular damage is oxidative stress. Cellular oxidative 
stress occurs when the production of reactive oxygen species surpasses the capability of 
the enzymatic antioxidants to regulate the levels of reactive oxygen species (ROS). ROS 
are derived byproducts from elemental oxygen, which can regulate cell functions. Low 
levels of ROS can help regulate cell functions, whereas high concentrations can alter 
macromolecules. Inadequate ROS balance can alter vascular homeostasis by inactivating 
nitric oxide (NO), which defends against vascular disease development [6, 17]. Nitric 
oxide, a vaso-protector, is a major target of superoxide. When superoxide reacts with NO, 
peroxynitrite (vasotoxic) is formed, which in return oxidizes BH4, a co-factor of eNOS, 
the enzyme responsible for producing NO [18]. Cells generate ROS in the vascular wall, 
in the mitochondria through oxidative phosphorylation, which can cause damage to 
lipids, proteins, and even mitochondrial DNA [19]. In response to a high concentration of 
ROS, antioxidant enzymes are induced to protect against not only reactive oxygen 
species, but other types of free radicals by scavenging the reactive molecules preventing 
the damage macromolecules. The imbalance between reactive oxygen species and 
antioxidant enzymes is a critical event in endothelial activation [20]. Endothelial 
activation refers to the state of endothelial cells inducing pro-inflammatory genes. 
Previous studies have found that ROS can also affect the production of pro-inflammatory 
cytokines in endothelial cells, which can lead to endothelial dysfunction. The progression 
of atherosclerosis begins when an overabundance of ROS oxidizes LDL, and decreases 
the bioavailability of NO, leading to endothelial dysfunction [20]. 
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Current Therapies for Atherosclerosis 
Previous research suggests that pharmacotherapy may interfere with the 
progression of atherosclerosis in more than one mechanism. Statins are inhibitors of 3-
hydroxy-3methylglutarylco-enzyme A (HMG-CoA) reductase. These drugs are suggested 
to lower the risk of developing CAD by lowering lipid levels, especially that of low-
density lipoprotein (LDL). In Ortego et al. exposure of mononuclear cells and vascular 
smooth muscle cells with atorvastatin showed that atorvastatin reduced the activation of 
NF-κB, decreasing pro-inflammatory cytokines and chemokines that signal for 
endothelial inflammation [21, 22].  Although statins are effective in decreasing 
inflammation, they are also effective antioxidants that reduce ROS and atherosclerosis 
[21, 23-25]. However, they have also been linked to myalgia, diabetes, and neurological 
problems [26-30]. With atherosclerosis affecting over 90 million people in the U.S. alone, 
it is a major health concern. Although there are various therapeutic regimens, new 
treatments with minimal side effects are needed. 
Carbon Nanoparticles  
Pharmaceutical development has mainly been focused on drug delivery and drug 
efficacy. Appropriate drug delivery has limitations such as drug solubility, bio-
distribution, biotransformation, toxicity and several side effects. Recently, the 
interdisciplinary research area of nanomedicine has gained attention. The nanotechnology 
and biomedical disciplines have set a focus in developing nanoparticles as a new drug 
delivery system to increase the bioavailability and efficacy of drugs by delivering them to 
targeted tissues [31]. Three types of carbon nanomaterial, graphene, nanotubes, and 
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fullerenes, have remained the main source of interest in research due to their size, 
semiconductor capacity, optical, and thermal properties. Carbon has multiple forms of 
allotropes such as diamond, graphite, and fullerene, which can all be used to produce 
carbon nanomaterial. This is known as the top-down synthesis. There are two main 
approaches in the synthesis for nanomaterial, bottom-up or top-down. Nanoparticle route 
synthesis can control the sample size distribution. The top-down is a harsh synthesis 
approach which breaks down the starting material into smaller particles, this however 
provides a wide size distribution. The bottom-up approach is using precursors to 
synthesize nanomaterial, this method provides a closer nanoparticle size distribution. An 
example of bottom-up synthesis is the synthesis of carbon nanotubes via graphene, a 
carbon allotrope which serves as the building block for fullerene and nanotube synthesis. 
A single layer of graphene, a layer of hexagonal lattice carbon atoms, can be manipulated 
to “wrap” and form fullerenes, and are “rolled” to produce carbon nanotubes [32]. Of the 
many classes of nanoparticles, carbon nanodots have become a novel area of interest due 
to their superior properties.  
The discovery of quantum dots (QDs) was a major turning point in the synthesis 
of carbon nanodots. Quantum dots opened many potential bio-applications when they 
were discovered to have bright fluorescence, resistant to metabolic degradation, and were 
photo-stable. Quantum dots have been highly researched for their promising bioimaging 
properties. Negatively, their application is limited because of cellular toxicity, caused by 
heavy metals used in synthesis. They have also been documented to generate ROS, which 
activates the extrinsic and intrinsic apoptotic pathways [33, 34]. 
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Carbon nanomaterial that contains carbon allotropes has been linked to DNA 
damage and cytotoxicity. Hizmann et al. analyzed cell toxicity and DNA damage when 
human glioblastoma U87 cells were exposed to different types of graphene. When cells 
were exposed to pristine graphene, and reduced graphene oxide, cell viability decreased, 
and DNA damage was observed [35]. With the discovery of carbon nanoparticles as 
promising therapeutic agents, biocompatibility and cytotoxicity need to be examined [36-
38].  Diamond nanoparticles have also been promising bio-imaging agents, but studies 
had shown that when HeLa cells were exposed to diamond nanoparticles in serum-free 
media, high cytotoxicity was evident after 6 hours. Another study showed that diamond 
nanoparticles could damage the DNA of embryonic stem cells [39, 40]. While this may 
have some therapeutic effects for cancer treatment, it is necessary to reduce cytotoxic risk 
in healthy cells.  The ideal carbon nanomaterial needs to have higher cell viability and 
retain QD properties for biomedical applications.  
Carbon Nanodots (CNDs) Novel Nanoparticles  
Carbon nanodots were accidentally discovered as fluorescent residue impurities 
after the synthesis of carbon nanotubes. They have a spherical or quasispherical structure, 
and their size is typically below 10nm. Carbon nanodots that are surface functional group 
rich have high solubility. Like QDs, they possess photoluminescence (PL) and rely on 
excitation, ranging from UV to visible light, and the emission produced may range from 
the UV to NIR light. Studies have linked CND photoluminescence to nanoparticle size 
and surface functional groups [41, 42].  By controlling the synthesis route used, different 
quantum yields (QY) may be acquired, resulting in different photoluminescence 
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properties. One method that has been adapted to the synthesis process is the use of 
molecules such as polyethylene glycol for surface passivation of CNDs to increase QY. 
Zhu et al. synthesized CNDs with citric acid and ethylenediamine as precursors, and the 
CNDs produced had a high QY of 80.6%, studies have also documented using precursors 
with amino groups to produce a high quantum yield [43-45] without the use of surface 
passivation. Unlike QDs, carbon nanodots use carbon precursors for synthesis (bottom-up 
synthesis), this is commonly referred to as green synthesis.  Carbon nanodots have been 
documented to have low toxicity and high quantum yield which is relative to the emitted 
fluorescence.  
This makes carbon nanodots candidates for biomedical applications such as 
therapeutic delivery and bio-imaging. With so many potential applications, the fine-
tuning of carbon nanodot synthesis has been a major drive in all the research tangents 
regarding nanodots and medicine. For example, although advances in CND synthesis 
have been made, a major push is to develop carbon nanodots that can go into the nucleus. 
Previous studies have shown that most CNDs remain in the cytoplasm of cells after 
exposure [46, 47]. Nuclear targeting drug delivery would be optimal for cancer therapy, 
increasing the efficacy of drugs which have multiple side effects. However, it is known 
that positively charged CNDs are taken in by the cells, but only negatively charged CNDs 
could interact with the nucleus. This dilemma led to the fabrication of zwitterionic carbon 
nanodots that have functional groups with both charges to facilitate nuclear translocation.   
Studies have also previously shown that carbon nanodots can track biological 
processes inside cells [48], deliver doxorubicin to cancer target cells [49, 50], and 
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scavenge radicals during oxidative stress [51, 52].  Das and colleagues synthesized CNDs 
from date molasses through microwave irradiation. After characterizing the nanomaterial, 
the biological application was tested on MG-63 human osteosarcoma cells. This synthesis 
not only showed high biocompatibility, but the carbon nanodots also showed high 
scavenging properties [53]. Zhang et al. used a single step microwave route to synthesize 
soluble carbon nanodots with citric acid and urea as precursors. Characterization of these 
carbon nanodots showed a spherical structure with an average size of 3nm with 
carboxylic and amino functional groups. Fluorescence emission spectrum was also 
analyzed in different wavelengths, and it was found that the highest emission peak was at 
an excitation peak of 360 nm with an emission peak of 454 nm. These same carbon 
nanodots were analyzed for antioxidant activity through the nitrogen-centered 2-2-
diphenyl-1-picrylhydrazyl radical ( DPPH•) assay which is a well-established assay used 
to measure antioxidant activity [54-56] by measuring the absorbance of  DPPH•. The 
results showed that with increasing concentrations of CNDs, antioxidant activity 
increased, suggesting the potential bio-application of carbon nanodots in scavenging free 
radicals [57].  
Atherosclerosis is an inflammatory disease that narrows the walls of the arteries 
via plaque buildup. Previous studies demonstrate that endothelial inflammation induced 
by TNFα plays a fundamental role in the initiation and progression of atherosclerosis. 
The transcriptional regulation of cytokines and vascular adhesion molecules are 
responsible for leukocyte adhesion to activated endothelial cells [58, 59]. Currently, there 
is not satisfactory anti-inflammatory drug therapy. With the incidence of cardiovascular 
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diseases expected to continue to increase, new treatments need to be developed. ROS are 
reactive free radicals containing oxygen and are known to play an important role in 
endothelial inflammation.  Although previous studies have suggested the role of CNDs as 
free radical scavengers, the effect of carbon nanodots on the vascular system has not been 
reported, nor has its potential role in anti-inflammation against endothelial dysfunction.  
The primary goal of this study was to investigate the role of CNDs in the 
modulation of TNFα-induced vascular inflammation both in vitro and in vivo.  EA.hy926 
was used as the in vitro cell model; this cell line is one of the best characterized vascular 
endothelial cell lines. These cells have been extensively used as a model for 
cardiovascular research to analyze expression of pro-inflammatory markers and 
leukocyte adhesion to activated cells. ApoE-/- mice have been used widely to study the 
pathophysiology of atherosclerosis. It is the most commonly used rodent model to 
examine events leading to plaque development and to test potential protective treatments 
for atherosclerosis [60-64].  I hypothesize that CNDs with antioxidant properties can 
protect against vascular inflammation. Accordingly, the study aims were designed to 1) 
examine in vitro carbon nanodot uptake and cytotoxicity in EA.hy926 endothelial cells; 
2) investigate  the role of CND in the modulation of TNFα-induced expression of pro-
inflammatory genes and possible underlying mechanism(s); 3) examine the effects of 
carbon nanodots in Apo E-/- mice, a biological model of atherosclerosis. The possible 
impact of the role of carbon nanodots in vascular inflammation may provide new 
information on the potential application of carbon nanodots as an effective treatment for 
inflammatory disorders such as atherosclerosis.  
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CHAPTER II 
 
MATERIALS AND METHODS 
 
 
Materials 
 EA.hy926 endothelial cells from ATCC were purchased. For cell culturing 
Dulbecco's Modifies Eagles Medium (DMEM) were acquired from Gibco (12100-061), 
both the fetal bovine serum (FBS 26140-079) and penicillin streptomyosin (15140-122) 
were purchased from Gibco. For cell viability thiazolyl blue tetrazolium bromide was 
bought from Sigma (298-93-1), and Invitrogen molecular probe kit for flow cytometry 
was acquired (BMS306F1-300). PermaFluor Mountant for imaging came from 
ThermoFisher Scientific (TA-006-FM), and we used MitoTracker Red CMXRos 
manufactured by Life Technologies (M7512). For the purpose of gene expression the 
following reagents were purchased from Invitrogen; 10mM dNTP (18427-013), random 
primers (S8875), M-MLV reverse transcriptase (28025-013), 5X first strand buffer 
(Y02321). SYBR-Green was purchased from Applied Biosystems (4367659), and primer 
sequences (see sequences in qRT-PCR section) were sold by Eurofin. Apolipoprotein 
mice were obtained from Jackson Laboratory (002052).  
Cell Culture 
Human endothelial cells EA.hy926 were purchased from ATCC and grown in 
complete Dulbecco's Modifies Eagles Medium (DMEM) containing 10% fetal bovine 
serum and 1% penicillin-streptomycin. Cells were cultured in 72cm2 Cellstar culture 
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flasks and  kept in a humidified incubator at 37ºC and 5% CO2. Cells were replenished 
with fresh media every two days; cells were passaged according to ATCC’s sub-culturing 
procedure when cells were 90% confluent. 
Carbon Nanodot (CND) Synthesis  
Carbon-nanodots (CNDs) were synthesized by Wendy Zhang, a Ph.D. student in 
Dr. Jianjun Wei’s lab at the Joint School of Nanoscience and Nanoengineering. The 
CNDs were synthesized by mixing 0.96g of citric acid (CA), 1 mL of Ethylenediamine 
(EDA) in 1 mL of deionized water. The solution was heated in a microwave synthesizer 
(CEM Corp 908005) at 300W for 10 minutes. To purify the CNDs, the solid was 
dissolved in DI water and dialyzed through a dialysis membrane with MWCO (molecular 
weight cut-out) of 1000Da for 24 hours. 
Characterization of CND 
Atomic force microscopy (AFM) was performed by JSNN to analyze morphology 
and size. To study the chemical content and the structure of the CNDs, Fourier transform 
infrared spectroscopy (FTIR) was done by JSNN. Using Cary fluorescence 
spectrophotometer, the fluorescence intensity peaks were measured to find the emission 
and excitation wavelengths for the carbon nanodots. The CND concentration in distilled 
water for analysis was 0.06 mg/mL.  
CND Treatments  
EA.hy296 cells were treated with CNDs with various concentrations for 24 hours 
in Hank’s Balance Salt Solution (HBSS) media. Before treating cells with CNDs, cells 
  
13 
 
were rinsed with 7 mLs of 1X Phosphate Buffered Saline (PBS), the solution was 
decanted, and the treatment media was added. 
CND Uptake Assay 
Cells were treated at a time-dependent and dose-dependent manner. When 
treatment was over, treatment media was decanted, cells were rinsed twice with 7 mLs of 
1X PBS. Cells were harvested using a cell scraper and centrifuged at 5000 rpm for 5 
minutes at 4ºC. The supernatant was decanted, 900 µL of 1X PBS was used to suspend 
the cells. A black opaque 96 well plate was used to transfer 300 µL of suspended cells in 
technique triplicates. The plate was read using Synergy 2.0 well plate reader, 
fluorescence 360/460 top 400nm.  
MTT Assay 
EA.hy926 cells were cultured in a 48 well plate; cells were treated with 300 µL of 
various concentrations of carbon nanodots in HBSS media for 24 hours. After 24 hours, 
media was decanted, and cells were rinsed twice with 200 µL of 1X PBS. Low serum 
DMEM (0.5% FBS) was used to dilute 3-(4,5-dimethythiazol- 2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) to a concentration of 0.2 mg/mL. The treated cells were 
incubated with 300 µL of the diluted MTT; plates were kept in a humidified incubator at 
37ºC and 5% CO2 for 2 hours. After incubation, cells were rinsed with 1X PBS, and 300 
µL of dimethyl sulfoxide (DSMO) was added. The plate was shaken at medium speed for 
7 minutes before absorbance was measured using Synergy 2.0 plate reader at 570nm.  
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Flow Cytometry Assay 
Cells were treated in HBSS media and various concentrations of carbon nanodots 
for 24 hours; treatment media was collected, cells were trypsinized, cold DMEM was 
used to neutralize trypsin and collected. Cells were centrifuged at 1000 rpm at 4ºC for 5 
minutes. Cells were washed with PBS, counted, and centrifuged in Eppendorf centrifuge 
tubes at 5000 rpm at 4ºC for 5 minutes. The supernatant was decanted, the resulting pellet 
was re-suspended in the appropriate volume of 1X binding buffer to produce target cell 
concentration range of 1 x 105 and 1 x 106 cells per mL. In a flow cytometry tube, 100 µL 
of suspended cells were transferred, 5 µL of Annexin-V-FITC was added, followed by 1 
µL of 7-AADD. Cells were kept in ice and incubated in the dark for 15 minutes. After 
incubation 400 µL of the 1X binding buffer was added to the cells and samples were 
analyzed using Guava® easyCyte Flow Cytometer. 
Quantitative Real Time Polymerase Chain Reaction  
EA.hy926 cells were treated with CNDs only and 0.5ng TNFα co-treatments. 
Cells were rinsed after treatment, and 1 mL of RNA isolation reagent was added to the 
treatment plate. Cells and solution were then transferred to a microcentrifuge tube and 
incubated for 5 minutes at room temperature (RT). After incubation, 200 µL of 
chloroform was added, followed by a 3 min RT incubation. The RNA extraction 
supernatant was then spun at 12000 rcf for 15 min at 4ºC.  The aqueous phase was 
transferred to another tube, and 500 µL of isopropanol was added and incubated for 
10mins RT. The supernatant was centrifuged at 12000 rcf for 10 min at 4ºC. The 
supernatant was decanted, and RNA pellet was washed twice with 1 mL 75% ethanol, 
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spun at 7400 rcf for 5 min at 4ºC. On the last wash, the supernatant was decanted, and the 
tube was inverted to air dry for 10 mins. The RNA pellet was eluted in 15 µL of DEPC 
water and incubated for 20 mins RT. RNA concentration was quantified, and cDNA was 
made after RNA was diluted to 500 ng/µL. Gene primer master mix was made, cDNA 
was diluted to a 1:9 ratio with DEPC water, 19 µL of the gene master mix was used per 
well, and 1µL of cDNA was used to plate.  
 
Table 1. Sequences of Primers Used For qRT-PCR. 
 
Primers and Sequences 
Target 
Gene  Forward (5’-3’) Reverse (3’-5’) 
GAPDH CGACCACTTTGTCAAGCTCA AGGGGTCTACATGGCAACTG 
CCL2 CCCCAGTCACCTGCTGTTAT TGGAATCCTGAACCCACTTC 
ICAM GGCTGGAGCTGTTTGAGAAC ACTGTGGGGTTCAACCTCTG 
IL-8 TAGCAAAATTGAGGCCAAGG AAACCAAGGCACAGTGGAAC 
 
 
Cell Fixation of CND Treatments 
Cells were grown on cover slips and treated for 24 hours with various CND 
concentrations in HBSS media. Cover slips were washed three times in 1X PBS twice 
and incubated in 3.7% PFA for 7 minutes. Cover slips were rinsed twice with 1X PBS 
following PFA fixation. To mount cover slips to slides, 15µl of PermaFluor Mountant 
media was used. Slides were left over night to set. Imaging was done using the Keyence 
BZ-X710 fluorescence microscope.  
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Cell Fixation of MitoTracker Red and CNDs 
Cells on coverslips were treated with CNDs for 24 hr in HBSS media. Cells were 
stained with MitoTracker Red and incubated with the stain 30 minutes prior to the end of 
the 24 hr CND treatment. Cells were washed three times with 1X PBS, incubated in 3.7% 
PFA for 7 minutes, cover slips were rinsed twice with 1X PBS. Cover slips were 
mounted onto slides using 15 µl of PermaFluor Mountant media. Slides were left over 
night in the dark to set; imaging was done with Keyence BZ-X710 fluorescence 
microscope. 
Antioxidant Sample Preparation 
Treated EA.hy926 endothelial cells were harvested by decanting the media, 
rinsing twice with sterile 1X PBS. Cells were then trypsinized using 1.5 mL of trypsin 
and incubated for 3-5 mins. Trypsin was canceled by adding 7 mLs of complete DMEM 
containing 10% fetal bovine serum; the collected cells were then centrifuged at 1000 rpm 
for 7 minutes at 4ºC. The pellet was suspended in 1 mL of PBS, transferred to a 
microcentrifuge tube and spun at 5000 rpm for 5 minutes at 4ºC. PBS was decanted and 
the pellet was suspended in 250 µL of tissue buffer (60Mm K2HPO4/KH2PO4 + 1mM 
EDTA pH 7.4 + 0.1% Triton-100). Cells were sonicated three times for 15 seconds with a 
5 second resting period in between. The sonicated cells were spun at 13000 rpm for 10 
minutes at 4ºC. The antioxidant supernatant was transferred to a sterile microcentrifuge 
tube and stored at -80ºC.  
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Total Protein Assay 
Pierce Coomassie (Bradford) Protein Dye was used for this assay, 800 µL of the 
dye was added to a test tube followed by 6 µL of antioxidant sample. For the standard, 10 
µL of BSA 1.48mg/mL was used the final volume in each test tube was 800 µL. 
Absorbance was read at 595nm. 
Total NADPH Quinone Oxidoreductase-1 (NQO1) Assay 
Antioxidant sample lysate was used for the assay. Light sensitive NQO1 reaction 
mixture was made using 12 mLs NQO1 Buffer (50mM Tris-HCL, 0.08% TritonX-100 
pH 7.5); 48 µL of 20 mM dichlorophenolindophenol (DCPIP) and 36 µL of 50mM 
nicotinamide adenine dinucleotide phosphate (NADPH). In a cuvette, 698 µL of the 
NQO1 reaction mixture and 2 uL of antioxidant lysate sample was added, inverted and 
immediately measured. Total NQO1 was obtained by reading the absorbance (600nm 
every 15 seconds for 3 minutes) using DU800 spectrophotometer.  
Glutathione Reductase (GR) Assay 
Antioxidant lysate samples were used for this assay. In a cuvette, 465 µL of GR 
buffer (50mM K2HPO4/KH2PO4 1mM EDTA pH 7.0), 60 µL of 20mM GSSG, and 15 
µL of the antioxidant sample (tissue buffer for blank) were added. The assay mixture was 
incubated for 3 minutes at 37 ºC in the DU800 spectrophotometer. After incubation, 60 
µL of 1.5Mm NADPH was added, cuvettes were inverted with parafilm and read at 37 
ºC, 340nm, 30-second intervals for 5 minutes. 
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Glutathione S-Transferase (GST) Assay 
Light sensitive GST reaction mixture was made with 10 mL GST buffer (0.1M 
K2HPO4/KH2PO4 pH 6.5), 30mg of bovine serum albumin (BSA), 200 µL of 50mM 1-
chloro-2,4-dinitrobenzene (CDNB) in ethanol, and 100 µL of 100mM GSH. DU800 
spectrophotometer was blanked with a cuvette containing 585 µL of the reaction mixture 
and 15 µL of tissue buffer. Antioxidant lysate samples were used for this assay. Each 
cuvette for each sample contained 585 µL of the reaction mixture and 15 µL of the 
sample. The cuvette was inverted to mix the sample and read at 340nm every 30 seconds 
for 5 minutes at 25ºC.  
Animal Dosing 
Thirty-six 5-week-old male ApoE-/- mice were purchased from the Jackson 
Laboratory. Mice were randomly placed in cages (3 animals per cage), and held in 
isolation for one week. The animals were fed an atherogenic diet (15% fat by weight; 
0.25% cholesterol, Harlan Teklad) one week prior to animal dosing. Cages were picked at 
random for dosing, CNDs were diluted to the desired concentrations with sterile saline. 
All mice were dosed daily via intraperitoneal injection for eight weeks. All experimental 
mice were dosed in the same manner given different concentrations of carbon nanodots in 
saline (0.1 mg/kg BW, 0.1 mg/kg BW, 0.5 mg/kg BW, 2.5 mg/kg BW). Mice were fed 
atherogenic diet for the duration of this study. After the 8-week dosing period was over, 
animals were humanely euthanized with isoflurane, and the cardiac puncture was 
performed afterward, along with cervical dislocation. Tissue samples were collected 
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including aorta, kidneys, brain, heart, spleen, etc.  Selected samples were placed in 10% 
buffered formaldehyde for histopathological examination.  
Histology Assessment of Kidney, Liver and Aorta 
Three samples per experimental group were collected for the liver, kidney, and 
aorta histology. Hematoxylin and eosin tissue slides were prepared by AML 
Laboratories. Imaging of the samples was done using Keyence BZ-X710. Images were 
sent to collaborators at Michigan State Medical School and analyzed by our collaborator 
Robert Sigler DVM, Ph.D., ACVP, Clinical Professor and Director, In-Vivo Animal 
Core.  
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CHAPTER III 
 
RESULTS 
 
 
Characterization of CNDs 
 
Carbon nanoparticle synthesis provides unique features [40-42] to nanomaterial. 
The nanoparticles used in this study possess their own fluorescence. Prior to conducting 
experiments, we verified the photoluminescence characterization of carbon nanodots 
through ultraviolet-visible spectrophotometry (Fig 1A). The excitation and emission of 
CNDs at a concentration of 0.06 mg/mL was measured to be 350 nm and 461 nm 
respectively. The fluorescence of nanomaterial can be excitation-independent or 
excitation-dependent. To further verify the photoluminescence properties, we measured 
the emission of 0.06 mg/mL CNDs for the following wavelengths; 320 nm, 340 nm, 360 
nm, 380 nm, 400 nm, and 420 nm. Figure 2A shows that the emission peaks for different 
excitations are found at about 460 nm, verifying that the synthesized carbon nanodots are 
excitation independent.  
CND Uptake in EA.hy926 Endothelial Cells 
Photoluminescent characterization was important for our experiments to study 
CND uptake using fluorescence microscopy. Using the excitation and emission spectra of 
carbon nanodots, fluorescence imaging was done after a 24 hr exposure of 0.6 mg/mL 
CNDs in EA.hy926 endothelial cells. The DAPI channel was used to observe
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fluorescence in EA.hy926 cells after CND exposure. Figure 2A shows that as expected, 
the control group does not have fluorescence under the DAPI channel. The cells treated 
with 0.6 mg/mL CND for 24 hr show fluorescence, indicating that the nanomaterial goes 
into the cells. To further verify if there was a change in fluorescence with increasing 
concentration exposure of CNDs EA.hy926 cells were exposed to 0 mg/mL, 0.3 mg/mL, 
0.6 mg/mL, and 1.2 mg/mL of CNDs (Fig. 2B). Panel B shows a visible increase in 
fluorescence that is dose-dependent.  Prior to quantifying the amount of carbon nanodots 
that enter the cells, a carbon nanodot standard was created by measuring the fluorescence 
of known concentrations (Fig. 3C). A line of regression was created and used to calculate 
CND uptake. As shown in figure 4A, EA.hy926 cells were treated with various 
concentrations of CNDs for 24 hr and uptake was quantified. CND uptake with the tested 
concentrations was found to be dose-dependent. CND uptake analysis shows that 
nanomaterial uptake is also time-dependent (Fig. 3B).   
Cell Viability Determined by MTT Assay  
Any substance has the potential to be toxic when the chemical reaches a sufficient 
concentration. The effect of carbon nanodots on cell viability was measured through 
MTT assay, which measures a cell’s metabolic activity {Riss, 2004 #106}.  The CND 
concentrations used to analyze cell viability through MTT were 0 mg/mL, 0.0003 
mg/mL, 0.003 mg/mL, 0.03 mg/mL, 0.3 mg/mL, 0.6 mg/mL, and 1.2 mg/mL. Hydrogen 
peroxide, known to affect metabolic activity was used as the positive control {Cossu, 
2012 #126}. Cell viability was analyzed in a time-dependent manner. Figure 4A shows 
that after a 3 hr incubation when compared to the control, cell viability does not change. 
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After 6 hr CND exposure (Fig 4B), the highest concentration shows cytotoxicity. As 
shown in Fig 4C, EA.hy926 endothelial cells treated with 0.6 mg/mL and 1.2 mg/mL 
CND show a decrease of 9.8% and 14.5% in cell viability after 12 hr incubation. 
Following a 24 hr exposure to CNDs, 0.6 mg/mL and 1.2 mg/mL showed significant 
cytotoxicity compared to the control (Fig 4D). 
Cell Viability Determined by Flow Cytometry 
To further confirm the effect of carbon nanodots on cell viability, the Annexin-
FITC flow cytometry assay was used to analyze cells undergoing apoptosis and necrosis. 
Cells undergoing apoptosis are identified through the binding of the Annexin V-FITC 
conjugate to phosphatidylserine, a phospholipid cell membrane component normally 
located in the inner leaflet of the membrane that translocates to the outer surface during 
apoptosis. The conditions used for flow cytometry are the same used to analyze cell 
viability through MTT assay. Figure 5A shows EA.hy926 cell viability after a 12 hr CND 
exposure; there is no cell viability difference between the control and the CND 
treatments. Flow cytometry plots are read in the following manner; the viable cells are 
plotted in the bottom left quadrant, the cells undergoing early apoptosis are in the bottom 
left quadrant. The top left quadrant is where necrotic cells are a plot, and the top right 
quadrant is where late apoptotic cells are plotted. As depicted in figure 5B, after a 24 hr 
incubation period with varying CND concentrations, there is a significant cell viability 
decrease of 20% in the highest CND concentration used when compared to the control.  
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Fluorescence Imaging of Mitochondria and CNDs  
Cells were treated with 0 mg/mL, 0.3 mg/mL, 0.6 mg/mL, AND 1.2 mg/mL of 
CNDs for 24 hr, mitochondria were stained with MitoTracker Red for 30 min. 
Fluorescence imaging was done as seen in figure 6. Imaging was done for both the 
mitochondria and the CNDs with the use of different channels in the fluorescence 
microscope, followed by the overlay imaging. 
Effects of CNDs on TNF-α-Induced Expression of Pro-Inflammatory Genes 
Atherosclerosis is an inflammatory disease mediated by pro-inflammatory 
markers. Therefore we used qRT-PCR to measure the effects that CNDs have on TNF-α-
induced mRNA levels of several pro-inflammatory genes. EA.hy926 cells were co-
treated with 0.5 ng TNF-α and increasing concentrations of CNDs for 24 hr.  Figure 7A 
shows an increase in the relative gene expression of CCL2 induced by co-treatment. 
Compared to TNF-α, 0.003 mg/mL and increasing concentrations of CND co-treatments 
show a significant increase in gene expression. ICAM gene expression (Fig 7B) shows a 
statistically significant decrease in all co-treatments when compared to TNF-α-induced 
expression of ICAM. As shown in figure 6C, there is a significant decrease in mRNA 
levels of IL-8 in the higher concentration of CND co-treatments when compared to TNF-
α only.  
 
Effects of CNDs Alone on Expression of Pro-Inflammatory Genes 
After analyzing mRNA levels of co-treatment with TNF-α, it was crucial to 
analyze the effect of CNDs alone on pro-inflammatory markers of atherosclerosis. We 
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studied the effect of gene expression with increasing concentrations of carbon nanodots 
in EA.hy926 cells for 24 hr. Figure 8A shows that there are CND dosages that decrease 
the levels of CCL2 mRNA. The gene expression for ICAM (Fig 8B) shows that 0.03 
mg/mL significantly reduces the expression of ICAM after 24 hr. Interleukin-8 mRNA 
levels are affected after 24 hr by CNDs concentrations of 0.0003 mg/mL, and 0.03 
mg/mL (Fig 8C).  
Increase in NOQ1 Activity by Carbon Nanodots After 24 hr 
To further examine intracellular effects of CNDs we measured the activity of 
phase II detoxifying enzymes that are important to xenobiotic biotransformation and 
excretion. Cells were treated for 24 hr with 0 mg/mL, 0 mg/mL, 0.0003 mg/mL, 0.003 
mg/mL, 0.03 mg/mL, 0.3 mg/mL of CNDs and samples were prepared to measure the 
activity of phase II detoxifying enzymes through enzyme kinetic assays. NQO1 activity 
was significantly increased in 0.0003 mg/mL, 0.003 mg/mL, and 0.03 mg/mL of CND 
treatments, as seen in figure 9A. The activity of glutathione s-transferase (Fig 9B), and 
glutathione reductase (9C) did not differ from the control.    
Carbon Nanodots Have No Effect in Apo E -/- Mice Body Weight (BW) 
Apo E -/- mice are a biological model for atherosclerosis pathophysiology. Mice 
were dosed daily with CNDs for 8 weeks via intraperitoneal dosing (0 mg/mL BW, 0.1 
mg/mL BW, 0.5 mg/mL BW, 2.5 mg/mL BW). Body weight of every group was 
recorded. The values shown are the body weight at the end of the week. Week (-1) shows 
the weight of the animals before they were fed the atherogenic diet, week zero showed 
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the body weight of the groups when dosing started. When compared to the control group 
for the week, carbon nanodots do not affect body weight as shown in figure 10.  
Histology Assessment of the Aorta, Kidney, and Liver 
Samples were sent to AML Laboratories for processing and hematoxylin and 
eosin staining. Figure 11 shows that the aorta of wild-type mice (C57BL/6 mice) appear 
to have normal aorta. Apo E -/- show a structural irregularity of the aorta, and 
accumulation of fibrous tissue. Whereas the aorta of CND dosed mice may show a 
decrease in aortic plaque formation. Histological samples of the liver show swollen 
hepatocytes and lipid accumulation. Samples from mice dosed with CNDs have a visible 
decrease in hepatic lipidosis (Fig 12). Imaging for kidney histology across all 
experimental groups seems to be unchanged compared to the wild-type mice (Fig 13).  
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CHAPTER IV 
 
DISCUSSION 
 
 
The leading cause of death worldwide is cardiovascular disease. The silent 
progression of plaque formation on blood vessels, or atherosclerosis, causes ischemia 
leading to more pathological cardiovascular diseases such as coronary artery disease 
(CAD), myocardial infarction (MI), transient ischemic attack (TIA), and acute coronary 
syndrome (ACS). The epidemiology of the cardiovascular disease is a universal health 
concern driving research for novel treatment options. Nanomedicine is the application of 
nanoparticles, the material below 100 nm in size, for medical purposes. This 
interdisciplinary field has been a growing in the last decade, increasing the classes of 
nanoparticles synthesized, as well as improving the synthesis technique [36, 65-67]. 
Carbon nanodots are a new class of nanoparticles that are prospective candidates for 
medical applications.  
In this study, we have demonstrated that the emission peaks of citric acid- 
ethylenediamine (CA-EDA) synthesized carbon nanodots under different excitations are 
at about 460 nm, suggesting that the photoluminescence properties of this nanoparticle 
are excitation independent. Our results are consistent with previous reports that carbon 
nanodots can be excitation independent according to the synthesis method [36, 43, 65, 
66]. This excitation independent photoluminescence property (Fig 1A, 1B), allows for the 
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analysis of carbon nanodot uptake in EA.hy926 endothelial cells. Using 
spectrofluorometric measurement, our study demonstrated that nanodot uptake is both  
time and concentration dependent in endothelial cells (Fig. 3A, 3B). Carbon nanodot 
uptake by endothelial cells was further verified through fluorescence microscopy. 
Currently, there is limited literature in evaluating cellular uptake of carbon nanodot into 
living cells.  In this context, our results present for the first-time, direct evidence that 
carbon nanodot can enter the cell at a concentration as low as 0.03 ng/mL. The question 
that remains unanswered is how carbon nanodots enter endothelial cells. Quantum dots 
have been documented to enter HeLa cancer cells through macropinocytosis and cell 
receptor-mediated endocytosis [68, 69]. Due to shared characteristics, it remains under 
investigation whether the entry mechanism of carbon nanodots in the endothelial cells is 
like that of quantum dots in HeLa cancer cells.  
The cell membrane protects intracellular components against the surrounding 
environment. When xenobiotics enter cells, they may cause toxic or adverse effect if the 
levels reach high concentrations. Although previous studies have documented 
cytotoxicity of CNDs in different cell lines, cytotoxicity has not been analyzed in 
endothelial cells. Thus, it is important to determine not only potential toxic 
concentrations, but also the mechanism of toxicity of CNDs to endothelial cells. The first 
assay used to analyze cell viability was the MTT assay, which measures cell viability 
through metabolic activity. Our MTT results showed that carbon nanodot concentrations 
of up to 0.3 mg/mL do not affect cell viability for up to 24 hr (Fig 4D). It was observed 
that highest concentration of carbon nanodots used (1.2 mg/mL) caused a decrease in cell 
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viability after 6hr (Fig. 4B), and 0.6 mg/mL of CNDs shows cytotoxicity as early as 12 hr 
after exposure (Fig. 4C).  To further confirm the effects of CNDs on endothelial cell 
viability, the Annexin V-FITC with 7-AAD flow cytometry assay was further used.  Cell 
viability through flow cytometry revealed that after 24 hr, only 1.2 mg/mL of CND 
decreases cell viability through apoptosis (Fig. 5A). Thus, these results do not parallel our 
results from the MTT assay. While 0.6 mg/mL of CND was not shown to affect cell 
viability via the flow cytometry assay, the same concentration showed a decrease in 
metabolic activity after 12 hr using MTT assay. The highest concentration of carbon 
nanodots tested showed a decrease in cell viability via flow cytometry after 24 hr 
exposure (Fig. 5B), whereas with the MTT assay detected a significant decrease in cell 
viability after 6 hr.  
These inconsistent results are mainly due to different viability assays. Through the 
Annexin V conjugate assay, cells undergoing apoptosis are identified through the binding 
of the Annexin V-FITC conjugate to phosphatidylserine, which translocates from the 
inner leaflet of the membrane to the outer surface during apoptosis. In contrast, the MTT 
assay is dependent on the ability of a healthy cell to undergo mitochondrial reductase to 
convert MTT to formazan crystals, which can be visualized as purple crystals inside the 
cell. Therefore, this assay reflects metabolic cellular activity or mitochondrial function, 
rather than direct cell viability. In this context, our data shows that higher concentrations 
of CNDs may directly target on the mitochondria, disrupting cellular metabolic activity.  
Indeed, previous studies report that mitochondrion are reported to be one of the first sites 
to be affected by many xenobiotics [70, 71].  
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To further investigate the above phenomenon, the EA.hy926 endothelial cells 
were labeled with MitoTracker Red, which labels metabolically active mitochondria 
following treatment with various concentrations of CNDs. Fluorescence microscopy 
images were then taken of CND, and of the labeled mitochondria followed by overlay 
images of the CND and mitochondria fluorescence (Fig. 6). Our results demonstrated that 
it is likely that the location of CNDs and the mitochondria overlap, however, due to 
limitations of fluorescence microscopy, further analysis should be done through confocal 
microscopy to assess if CNDs and mitochondria co-localize, affecting cell viability. With 
confocal microscopy, the sample can be sectioned, decreasing off-focus imaging, and 
overlap with different channels can verify co-localization [72].  
Since Inflammation-induced mononuclear cell adhesion to activated endothelium 
lining is crucial for atherosclerosis, this study further analyzed the effect of CNDs on 
TNFα-induced endothelial inflammation. Previous studies demonstrate that TNFα-
induced endothelial inflammation plays a fundamental role in the initiation and 
progression of atherosclerosis. TNFα is a homotrimer cell signaling protein, or cytokine, 
which is known to activate the endothelium, creating an inflammatory response. Pro-
inflammatory mediators that play a crucial role in the progression of atherosclerosis are 
cytokines and surface adhesion molecules such as interleukin 8 (IL-8), intracellular 
adhesion molecule 1 (ICAM-1) and monocyte chemoattractant protein-1 (MPC-1/CCL2) 
[7-10]. Previous studies show that the gene expression decrease in IL-8 can reduce the 
progression of atherosclerosis [73-75]. The expression of ICAM-1 and other vascular 
adhesion molecules on the surface of endothelial cells is crucial to the progression of 
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plaque development because of their roles in firm monocyte adhesion to the damaged 
endothelium. ICAM-1 can bind to the function-associated antigen (LFA-1) on activated 
leukocytes; this process helps leukocytes migrate to the tunica intima [76]. Thus, these 
molecules have been widely accepted as excellent biomarkers of vascular dysfunction 
[77-80].  
Concurrent to previous studies [81, 82], our studies showed that exposure of 
EA.hy926 endothelial cells to TNF-α significantly induced the expression of IL-8, 
ICAM-1, and MPC-1/CCL2 indicating the critical role of these chemokines/adhesion 
molecules in TNF-α-induced vascular inflammation. TNF-α-induced IL-8 expression is 
decreased significantly with increasing CND exposure suggesting the decrease in IL-8 to 
activate and recruit leukocytes to the site of inflammation. Likewise, CND concentrations 
as low as 0.3 ng/mL also inhibited TNF-α -induced ICAM-1 expression. These results 
demonstrated the anti-inflammatory effect of CNDs in a dose-dependent manner. 
However, it remains to be investigated why the expression of MPC-1/CCL2 was 
increased with CND exposure. Also, our data showed that carbon nanodots alone could 
decrease basal levels of the target genes studied, suggesting that CNDs can decrease the 
basal inflammatory response.  
Studies have shown that NF-κB, a transcription factor, is crucial in regulating the 
expression of endothelial adhesion molecules and pro-inflammatory mediators which 
increase leukocyte adhesion and migration to the site of the dysfunctional endothelium 
[11, 12]. The inactive form of NF-κB is associated with the cytoplasmic inhibitory 
protein Ik-B in the inactive form. Xenobiotic stimulation can result in the degradation of 
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Ik-B, translocating the p50/65 heterodimer to the nucleus, and upregulating transcription 
of pro-inflammatory genes [83, 84]. In the development of atherosclerosis, TNFα induces 
the activation of NF-κB increasing the expression of pro-inflammatory genes which 
modulate leukocyte adhesion to damaged endothelium. However, it remains unknown if 
CNDs can protect vasculature against inflammation induced by TNF-α, via the NF-κB 
pathway.  
Aside from the nuclear translocation of NF-κB, endothelial dysfunction can be 
elicited by reactive oxygen species (ROS) such as superoxide, hydrogen peroxide, 
hydroxyl radical, and peroxynitrite [85-87]. These reactive oxygen species have been 
shown to regulate NF-κB activation through TNF-α and other pro-inflammatory 
cytokines [88]. Interestingly, TNF-α-induced vascular inflammation releases of both 
superoxide and hydrogen peroxide [89]. A main target of ROS is the oxidation of LDL. 
The oxidation of LDL is an important event in the accumulation of plaque because it is 
ingested by macrophages to form a prominent characteristic of plaque, the formation of 
foam cells [85-87]. Important antioxidants in vasculature that protect against oxidative 
stress by quenching ROS include glutathione (GSH), NQO1, GST and  GR [90]. NQO1 
is a cytoprotective enzyme, one of its many known functions include the 2 electron 
reduction of quinines, along with decreasing the radical formation of semiquinones and 
the resulting ROS [91]. An additional function is to sustain the levels of important 
antioxidants like ubiquinone and vitamin E by reducing their derivatives to antioxidants 
[92, 93]. It has also been established that NQO1 scavenges superoxide anion radicals, 
protecting vasculature from oxidative stress [91, 94]. Interestingly, studies have shown 
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that in cardiovascular tissue, NQO1 is expressed much higher levels than in other tissue 
types [95] . This project was also the first to study the effects of CNDs on antioxidant 
enzymatic activity in EA.hy926 endothelial cells.  Interestingly, our results show that 
only the activity of NQO1 increased (Fig. 9A). In agreement with previous studies 
outlining the significant role of NQO1 in the maintenance of vascular homeostasis [96], 
our data suggests that NQO1 may be a cytoprotective mechanism of carbon nanodots to 
protect against TNFα-induced endothelial inflammation. However, it is unclear how 
CNDs increases cellular NQO1 activity in endothelial cells. Activation of nuclear factor 
erythroid 2–related factor 2 (Nrf2)/Keap-1/ARE signaling has been proposed in 
concurrent studies, to play an important role in in expression of intracellular NQO-1 [97]. 
Further investigation is required to examine the nuclear translocation of Nrf2 to 
understand the effect of carbon nanodots on NQO1 enzyme activity. Understanding the 
mechanism of action by which carbon nanodots activate NOQ1 is important due to the 
important role of NOQ1 in regulating healthy vascular homeostasis.  
This project was also the first to study the effects of CNDs in atherosclerosis in 
vivo.  Apolipoprotein E deficient (Apo E -/-) mice are the animal model most widely used 
for atherosclerosis. Apolipoprotein E is a protein that is synthesized in the liver, the most 
important role of this protein is to transport cholesterol and lipids to different tissues. The 
deficiency of apolipoprotein E increases cholesterol levels in the bloodstream as it 
impairs the clearance of cholesterol by the liver [98].  To study the effects of CNDs in 
atherosclerosis Apo E -/- mice, different carbon nanodot dosages were given daily via 
intraperitoneal dosing for 8 weeks. The body weight was monitored weekly, and after 8 
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weeks of dosing, the mice were euthanized, and hematoxylin and eosin samples of the 
aorta, kidney, and liver were prepared and examined. The chronic inflammatory response 
to the damaged endothelial lining of vessels can cause the progressive accumulation of 
plaque in vessels which can be observed in the Apo E -/- mice aorta. Our results show 
that there may be a decrease in plaque formation in the aorta of Apo E -/- mice dosed 
with CNDs as compared to the Apo E deficient mice, suggesting that CNDs can 
ameliorate vascular function in atherosclerosis. Apolipoprotein E deficiency has been 
linked to an increase in oxidative stress [99, 100], which can lead to the oxidation of 
macromolecules, and the damage to vascular endothelial damage. In this context, the 
CND protective effect could be partially due to the scavenging properties of the carbon 
nanodots[24, 25, 79], which can protect the endothelium. The liver is important for 
cholesterol homeostasis, but it is also an important organ that metabolizes a major 
quantity of xenobiotics or drugs via the first pass effect before it reaches the bloodstream 
[101]. Our histology imaging shows lipid accumulation in Apo E knockout mice, which 
could be due to the inability to excrete cholesterol into bile. Consistent to our findings for 
the aorta, CND treatment appears to reduce hepatic lipid accumulation compared to the 
Apo E knockout mice. However, CND treatment did not affect on in kidney. In addition 
to our findings, the CND treatment did not affect the body weight of the Apo E -/- mice, 
which is consistent with previous animal studies that reported no significant body weight 
change or toxic effect on BALB/c mice dosed with 2.5 mg/mL of CNDs [102, 103] 
suggesting the safety of carbon nanodots.  
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In summary, our study provided a biological characterization of citric acid, and 
EDA synthesized nanodots in vitro and in vivo via EA.hy926 endothelial cells and Apo E 
knockout mice. Utilizing the intrinsic fluorescence of CND, it was found that incubation 
of EA.hy926 cells with CND resulted in a dose and time-dependent intracellular uptake 
of this nanoparticle. Higher concentrations of carbon nanodots seem to affect cellular 
viability through targeting mitochondria metabolic activity. However future studies 
should be designed to analyze the relationship between mitochondria and carbon 
nanodots. CND significantly inhibited TNF-α-mediated expression of IL-8 and adhesion 
molecule ICAM-1, two key molecules that are responsible for the activation and the firm 
adhesion of monocytes to activated endothelial cells for the initiation of atherosclerosis. 
CND treatment also increased the activity of NQO1 in EA.hy926 endothelial cells. In the 
animal study, it is suggested that the plaque formation in the aorta and hepatic lipid 
accumulation in the Apo E knockout mice are reduced with CND dosing. Our studies 
suggest that the anti-inflammatory effect of CND was likely due to the scavenging 
properties of CNDs and the upregulation of NQO1 activity (Fig. 14). However, the exact 
molecular mechanisms involved are largely unknown and remain to be investigated. To 
further understand the effect of carbon nanodots beyond that of atherosclerosis, the 
pharmacodynamics and pharmacokinetics need to be explored. The possible impact of 
carbon nanodots on vascular inflammation may provide new information on the future 
application of carbon nanodots as an effective treatment for inflammatory disorders such 
as atherosclerosis.  
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APPENDIX A 
 
FIGURES 
 
 
 
 
Figure 1. Characterization of CNDs. (A) Excitation and emission of carbon nanodots 
were characterized using Cary fluorescence spectrophotometer. Excitation intensity peak 
is at 350nm, and emission intensity peak is at 461nm. (B) CNDs are excitation 
independent; the emission was analyzed after CNDs were tested at several excitation 
wavelengths. The highest emission is reached at 360nm. 
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Figure 2. Fluorescence Microscopy of CND Treated Endothelial Cells.  (A) 
Fluorescence microscopy images of EA.hy926 human endothelial cells treated 
0.6mg/mL CNDs for 24 hr.  Carbon nanodot excitation and emission are similar to those 
used for the DAPI channel. Overlay image for the control shows no fluorescence; the 
CND treated cells shows fluorescence after 24 hr. Cells were imaged using Keyence 
microscope. (B) Fluorescence in EA.hy926 human endothelial cells treated with 
increasing concentrations of CNDs after 24 hr exposure. Panel A shows an increase in 
fluorescence with increasing concentrations, top left: control; top right: 0.3 mg/mL; 
bottom left: 0.6 mg/mL; bottom right: 1.2 mg/mL. Cells were imaged using Keyence 
microscope. (C) CND standard curve used to quantify CND uptake. The fluorescence of 
known concentrations of CNDs was measured in a microplate reader, a line of regression 
was created to calculate nanomaterial uptake in cells. 
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Figure 3. EA.hy926 Endothelial Cellular Uptake of CNDs. (A) Concentration-
dependent exposure of CNDs in endothelial cells. EA.hy926 endothelial cells were 
treated with CNDs in HBSS media in a concentration-dependent manner for 24 hrs. (B) 
Time-dependent analysis of CND uptake of endothelial cells exposed to 0.15 mg/mL.  
Fluorescence was quantified via Bio-Tek Synergy 2.0 microplate reader. Nanodot uptake 
was calculated through the use of a standard curve. All data represent mean ± SEM 
(n=3), T-test data analysis *p<0.05 vs. control. 
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Figure 4.  Cell Viability Determined by Colorimetric MTT Assay. EA.hy926 cells were 
treated with various concentrations of CNDs in HBSS media. H2O2  was used as a 
positive control. (A) Low and high concentrations of CNDs were used to treat endothelial 
cells for 3 hrs. (B) 6 hr carbon nanodot treatment on endothelial cells shows that the at 
1.2 mg/mL cell viability decreases. (C) Endothelial cells were treated with CNDs for 12 
hr, compared to the control, only the cell viability for highest concentration is 
statistically significant. (D) After 24 hr    exposure to CNDs 0.6 mg/mL 1.2 mg/mL are 
cytotoxic to endothelial cells. Data shown are mean ± SEM (n=3), 1- Way ANOVA, 
*p<0.05 vs. control.  
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Figure 5A. Cell Viability Analyzed Through the Annexin-FITC Flow Cytometry Assay 
After 12 hr Exposure. (A) EA.hy926 endothelial cells were exposed for 12 hr with 
various carbon nanodot concentrations; cell viability was quantified through the Nexin 
flow cytometry assay. Top row from left to right) control, 0.0003mg/mL CND, 
0.003mg/mL CND, 0.03mg/mL, (bottom row from left to right) 0.3mg/mL, 0.6mg/mL, 1.2 
mg/mL CND, 800µM H2O2 0 as the positive control treatments. When compared to the 
control, no condition was statistically significant. Data shown are mean ± SEM (n=3), 1- 
Way ANOVA, *p<0.05 vs. control. 
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Figure 5B. Cell Viability Analyzed Through the Annexin-FITC Flow Cytometry Assay 
After 24 hr Exposure. EA.hy926 cells were treated with HBSS media for 24 hours for the 
(top row from left to right) control, 0.0003mg/mL CND, 0.003mg/mL CND, 0.03mg/mL, 
(bottom row from left to right) 0.3mg/mL, 0.6mg/mL, 1.2 mg/mL CND, 800µM H2O2 0 as 
the positive control treatments. Cell viability for 1.2 mg/mL CND was the only condition 
that was statistically significant when compared to the control. Flow cytometry plots are 
shown to the right; quantified cell viability graph is on the left. Data shown are mean ± 
SEM (n=3), 1- Way ANOVA, *p<0.05 vs. control.  
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Figure 6. Fluorescence Imaging of CNDs and Mitochondria in EA.hy926 Endothelial 
Cells. Cells were exposed to 0.3 mg/mL, 0.6 mg/mL, and 1.2 mg/mL carbon nanodots for 
24 hr in HBSS media. MitoTracker Red was used to label active mitochondria. Keyence 
BZ-710 fluorescence microscope was used for imaging.  
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Figure 7. Effects of CNDs on TNF-α-Induced Expression of Pro-Inflammatory Genes. 
EA.hy926 cells were co-treated for 24 hours with various concentrations of carbon 
nanodots and 0.5 ng/mL TNF-α. Gene expression was normalized using GAPDH as the 
house keeping gene. (A) Gene expression of CCL2 genes induced by co-treatments. The 
data shows that the target gene is upregulated after co-treatment. (B) Gene expression of 
ICAM genes induced by co-treatments. Our data shows a gradual decrease in the target 
gene expression after co-treatments. (C) Gene expression of IL-8 genes induced by co-
treatments. The data shown shows a decrease in expression with increasing CND 
concentration co-treatments (data are in mean ± SEM, n=9, T-test data analysis, 
*p<0.05 vs. TNF-α). 
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Figure 8. CNDs Affect the Expressions of Pro-Inflammatory Genes. Cells were treated 
for 24hours various concentrations of carbon nanodots. mRNA levels were measured 
using qRT-PCR, Ct values were normalized to GAPDH expression. (A) MCP-1/CCL2 is a 
chemokine that recruits WBCS to the site of cellular damage. (B) ICAM/CD54 is a 
protein on endothelial cell surfaces that bind EC receptors for adhesion. , (C) IL-8 is a 
cytokine that causes WBC migration to the site of inflammation are pro-inflammatory 
genes of interest (data are in mean ± SEM, n=9, T-test data analysis, *p<0.05 vs. 
control). 
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Figure 9. Increase in NOQ1 Activity by CNDs After 24 hr. Antioxidant lysates were 
produced after CND exposure for 24 hrs in HBSS media. (A) NQO1 is an enzyme that 
scavenges for ROS; total activity was measured, when compared to the control 0.0003 
mg/mL and 0.03 mg/mL CND were statistically significant. (B)  The quantified GST 
activity for the conditions is not statistically significant compared to the control. (C) GR 
activity in the treatments is similar to the control, GR reduces GSSG to GSH, an 
important phase II enzyme. Data are in mean ± SEM (n=3),  T-test data analysis*p<0.05 
vs. control. 
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Figure 10. Average Weekly Body Weight of Apo E -/- Mice Dosed With CNDs Was Not 
Affected . Animal models were fed an atherogenic diet one week prior to dosing, before 
starting the diet, animals were weighted (week -1), average body weight was collected 
weekly. No statistical significance was found when experimental groups were compared 
to the control of that week. All data represent mean ± SEM (n=6), 1-Way ANOVA 
analysis. 
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Figure 11. Histology of Aorta in ApoE -/- Mice Dosed with CNDs Suggests a Decrease 
in Plaque Formation. ApoE -/- mice were dosed with carious concentrations of CNDs 
for 8 weeks via intraperitoneal dosing. Mice aorta samples were processed for 
hematoxylin and eosin staining. Top row left to right: C57 mice, ApoE -/-, ApoE -/- dosed 
with 0.1 mg/mL CND dosing; bottom row left to right: 0.5 mg/mL, 2.5 mg/mL CND 
dosing. Arrows indicate abnormal aorta structures. Keyence microscope was used for 
bright field microscopy; samples were sectioned at 5 microns. 
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Figure 12. CNDs May Affect Hepatic Lipidosis in Apo E Deficient Mice. Liver samples 
were processed and stained. Apo E -/- shows hepatic lipidosis due to apolipoprotein E 
deficiency. Histology imaging suggests that there seems to be a decrease in the 
accumulation of lipids in the liver with CND dosing. Arrow indicates hepatic lipidosis.  
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Figure 13. Carbon Nanodots Appear to Not Affect the Kidney. Samples were processed 
for hematoxylin and eosin staining; imaging was done using Keyence microscope. 
Analysis of histology implies that carbon nanodots do not affect the kidney. Arrow 
indicates glomerulus.  
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Figure 14. Diagram of Proposed Study: CND Modulation of TNF-α-Induced 
Endothelial Dysfunction 
 
